Английская Википедия:Aprocitentan
Материал из Онлайн справочника
Шаблон:Short description Шаблон:Infobox drug
Aprocitentan is an endothelin receptor antagonist active at both endothelin A and endothelin B receptors.[1] It is developed for resistant hypertension by Idorsia, which sold it to Janssen but purchased the rights back in 2023 for $343 million.[2]
Aprocitentan is an active metabolite of macitentan.[3]
References
Шаблон:Cardiovascular-system-drug-stub